{
    "clinical_study": {
        "@rank": "87217", 
        "brief_summary": {
            "textblock": "The safety and efficacy of CS-PHP-melphalan has been evaluated in a phase 3 trial conducted\n      in the same patient population as well as using the same melphalan dosing as proposed in\n      this study.  This expanded access protocol will provide an experimental alternative\n      treatment option for both physicians and patients until the Delcath CS-PHP System receives\n      marketing approval."
        }, 
        "brief_title": "Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver", 
        "condition": [
            "Metastatic Liver Cancer", 
            "Ocular Melanoma", 
            "Cutaneous Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Liver Neoplasms", 
                "Melanoma", 
                "Skin Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically proven ocular/cutaneous melanoma with liver-dominant unresectable\n             metastatic disease, defined as limited extra-hepatic disease and hepatic involvement\n             which would, in the Investigator's opinion, result in morbidity and eventual\n             mortality. Limited extra-hepatic disease considered acceptable includes:\n\n               -  up to 4 pulmonary nodules, each <1cm in diameter\n\n               -  retroperitoneal lymph nodes <1cm in diameter\n\n               -  resectable skin or subcutaneous metastases\n\n               -  asymptomatic bone metastases that have been, or can be, palliated with external\n                  beam radiation therapy\n\n               -  a solitary metastasis to any site that can be resected with limited morbidity or\n                  controlled with radiation\n\n          2. \u22651 measurable hepatic lesion per RECIST 1.1\n\n          3. Vasculature compatible with insertion of CS-PHP catheters, per baseline abdominal MRA\n\n          4. ECOG PS 0-2\n\n        Exclusion Criteria:\n\n          1. Chemotherapy, radiotherapy, or biologic therapy for the malignancy \u22641 month prior to\n             1st CS-PHP-melphalan infusion\n\n          2. Extensive prior radiotherapy, defined as treatment to \u226550% of marrow-containing bones\n\n          3. Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term\n             oral glucocorticoids taken currently or \u22643 mths prior to 1st CS-PHP-melphalan\n             infusion\n\n          4. Received an investigational product \u226430 days prior to the 1st CS-PHP-melphalan\n             infusion\n\n          5. History of orthotopic liver transplantation, untreated gastrinoma (i.e. gastric acid\n             hypersecretion) or prior Whipple procedure\n\n          6. Not recovered from side effects of prior therapy to \u2264 Grade 1 NCI CTCAE 4.03\n\n          7. Child's B or C cirrhosis, or clinical evidence of portal hypertension\n\n          8. Patients with >50% of liver replaced by tumor, histologic evidence of hepatic\n             dysfunction seen by laparoscopic liver biopsy\n\n          9. History or evidence of clinically significant cardiac disease such as symptomatic\n             arrhythmia, angina/ischemia, coronary artery bypass graft surgery or percutaneous\n             transluminal coronary angioplasty, uncontrolled atrial fibrillation, CHF with a left\n             ventricular ejection fraction <40%, uncontrolled hypertension (SBP >190 mmHg or DBP\n             >100 mmHg), HR outside normal range of 50-100 bpm for women and 45-100 bpm for men\n\n         10. History/evidence of clinically significant pulmonary or cardiac disease incompatible\n             with fitness to undergo general anesthesia\n\n         11. Uncontrolled diabetes mellitus or hypo/hyperthyroidism\n\n         12. Active uncontrolled infection\n\n         13. History of bleeding disorders or known unresolved venous shunting\n\n         14. Requirement for ongoing chronic anticoagulation\n\n         15. Evidence of intracranial abnormalities resulting in risk for bleeding with\n             anticoagulation\n\n         16. History of alcohol or drug abuse \u22646 mths\n\n         17. Other malignancy within 3 yrs before enrollment with the exception of curatively\n             treated basal or squamous cell carcinoma of the skin, or curatively treated cervical,\n             breast carcinoma in situ or prostate cancer\n\n         18. History of hypersensitivity to: melphalan or its components; iodine contrast that\n             cannot be controlled by premedication with antihistamines and steroids; latex\n\n         19. Known hypersensitivity to heparin in the presence of heparin-induced thrombocytopenia\n             antibodies\n\n         20. Inadequate hematological or renal function as indicated by any of the following:\n\n               -  Platelets <100,000/mm3\n\n               -  Hb \u226410 g/dL\n\n               -  Neutrophils <2,000/mm3\n\n               -  S Creat >1.5 mg/dL or measured creatinine clearance <60 mL/min/1.73 m2\n\n         21. Inadequate liver function as indicated by any of the following:\n\n               -  Tbili \u22653.0 mg/dL\n\n               -  INR >1.5\n\n               -  AST/ALT >5xULN\n\n         22. Pregnant or nursing\n\n         23. Positive pregnancy test in subjects of childbearing potential \u22647 days prior to first\n             CS-PHP-melphalan infusion\n\n         24. Women who are pre-menopausal (i.e. have had a menstrual period \u226412 months) who are\n             unwilling or unable to undergo hormonal suppression to avoid menstruation during\n             treatment\n\n         25. Sexually active females of childbearing potential and sexually active males with\n             partners of reproductive potential unwilling or unable to use contraception from\n             screening until at least 30 days after last administration of CS-PHP-melphalan"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "id_info": {
            "nct_id": "NCT01728051", 
            "org_study_id": "MEL 2009-01"
        }, 
        "intervention": [
            {
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Percutaneous Hepatic Perfusion", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melphalan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 22, 2013", 
        "link": {
            "url": "http://www.delcath.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "John Wayne Cancer Institute at Saint John's Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Englewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80112"
                    }, 
                    "name": "Sky Ridge Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612-9497"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center and Research Institute at University of South Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962-1956"
                    }, 
                    "name": "Carol G. Simon Cancer Center at Morristown Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "University of Pittsburg Cancer Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Label, Expanded Access Study of Melphalan Chemosaturation With the Delcath System in Patients With Ocular and Cutaneous Melanoma Metastatic to the Liver", 
        "overall_official": [
            {
                "affiliation": "Sky Ridge Medical Center", 
                "last_name": "Charles W Nutting, DO", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H. Lee Moffitt Cancer Center and Research Institue at University of Southern Florida", 
                "last_name": "Jonathan Zager, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "John Wayne Cancer Institute at Saint John's Health Center", 
                "last_name": "Mark Faries, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Univeristy of Pittsburg Cancer Center", 
                "last_name": "James F Pingpank, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Carol G. Simon Cancer Center at Morristown Memorial Hospital", 
                "last_name": "Eric D Whitman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Maryland", 
                "last_name": "H. Richard Alexander, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "No longer available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728051"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Delcath Systems Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Delcath Systems Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "October 2013"
    }
}